Evommune Inc (NYSE: EVMN) is a clinical-stage biopharmaceutical company developing treatments for immune-mediated diseases. The company generates no product revenue as of the fiscal year ended December 31, 2025, operating entirely on capital raised through equity financings, including an initial public offering completed in November 2025. Evommune has in-licensed and sublicensed drug candidates through agreements with Dermira Inc (December 2020), AprilBio Co. Ltd (June 2024), and Maruho Co. Ltd (September 2023 and March 2024). The company used $76.4 million in operating cash in FY2025 versus $58.2 million in FY2024, and raised $220.8 million in financing cash flows in FY2025, primarily from its IPO proceeds. Evommune is headquartered in Palo Alto, California, and listed on the New York Stock Exchange. Its pipeline is advancing through clinical development, requiring continuous external financing to fund operations.

Revenue model

No product revenue as of FY2025. The company is funded through equity offerings, including its November 2025 IPO and a February 2026 securities purchase agreement. Future revenue, if any, would depend on clinical development outcomes and potential commercialization or partnering arrangements.

Products and services

Clinical-stage product candidates for immune-mediated diseases, in-licensed from Dermira Inc (license effective December 2020), AprilBio Co. Ltd (license effective June 2024), and sublicensed via agreements with Maruho Co. Ltd (September 2023 and March 2024). Specific drug candidate names and clinical stage details are not detailed in the available filing excerpts.

Customers and end markets

No commercial customers as of FY2025. End markets are in immune-mediated and inflammatory diseases, based on the company's licensing activity and clinical trial operations referenced in the filing.

Value-chain role

Drug developer and licensor. Evommune in-licenses assets from external parties, conducts clinical development, and holds sublicensing rights. It relies on third-party manufacturers, clinical research organizations, and external collaborators to advance its pipeline.

Geographic exposure

Headquartered in Palo Alto, California. Data privacy obligations reference U.S., EU, UK, New Zealand, and Australia regulations, indicating some international clinical trial or operational activity, though geographic revenue breakdown is not applicable given pre-revenue status.

Source: SEC 10-K, filed 2026-03-05

Industry: Pharmaceutical Preparations